Assembly Biosciences (NASDAQ:ASMB) Price Target Raised to $43.00 at Guggenheim

Assembly Biosciences (NASDAQ:ASMB) had its price target lifted by Guggenheim from $39.00 to $43.00 in a research note published on Monday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

ASMB has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Wall Street Zen raised shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday, March 29th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research report on Thursday, March 26th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Assembly Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $42.75.

Assembly Biosciences Stock Performance

Shares of ASMB stock opened at $29.22 on Monday. Assembly Biosciences has a one year low of $7.75 and a one year high of $39.71. The company’s 50-day moving average is $28.04 and its 200 day moving average is $30.14. The company has a market capitalization of $463.52 million, a price-to-earnings ratio of -39.49 and a beta of 1.15.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, beating the consensus estimate of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The company had revenue of $42.47 million for the quarter, compared to the consensus estimate of $7.42 million. As a group, research analysts predict that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Institutional Trading of Assembly Biosciences

A number of institutional investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at about $147,000. Virtus Investment Advisers LLC purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at about $251,000. Susquehanna Portfolio Strategies LLC purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at about $473,000. Superstring Capital Management LP purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at about $2,220,000. Finally, Millennium Management LLC boosted its holdings in shares of Assembly Biosciences by 354.6% during the 4th quarter. Millennium Management LLC now owns 98,221 shares of the biopharmaceutical company’s stock valued at $3,340,000 after acquiring an additional 76,613 shares during the last quarter. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.